Drug Profile
C 08001
Alternative Names: C08001; Carvedilol CR INNOPHARMAX; Inno-C08001Latest Information Update: 25 May 2022
Price :
$50
*
At a glance
- Originator INNOPHARMAX
- Class Antihypertensives; Carbazoles; Ethanolamines; Heart failure therapies; Ischaemic heart disorder therapies; Phenyl ethers; Propanolamines; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha beta adrenergic receptor antagonists; Beta-adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Heart failure; Hypertension; Myocardial infarction
- No development reported Cardiovascular disorders
Most Recent Events
- 25 May 2022 Phase-III clinical trials in Heart failure in Taiwan (PO) (Immediate release) (Controlled release) before May 2022 (INNOPHARMAX pipeline, May 2022)
- 25 May 2022 Phase-III clinical trials in Hypertension in Taiwan (PO) (Immediate release) (Controlled release) before May 2022 (INNOPHARMAX pipeline, May 2022)
- 25 May 2022 Phase-III clinical trials in Myocardial infarction in Taiwan (PO) (Immediate release) (Controlled release) before May 2022 (INNOPHARMAX pipeline, May 2022)